Q Bio is a technology company that develops a clinical digital twin platform combining AI, physics, and biology to automate and transform the physical exam process. Its platform creates a comprehensive virtual model of a patient’s physiological and genetic data, enabling personalized health monitoring, risk assessment, and preventive care. Q Bio primarily serves healthcare providers and patients by offering detailed insights into health status and future risks, particularly for chronic diseases like cancer, diabetes, and cardiovascular conditions. The company has demonstrated growth momentum through successful deployment of its platform in its Redwood City clinic and partnerships with major longevity and healthcare organizations[1][2][4].
Founded in 2015, Q Bio was established by Jeffrey Kaditz, a serial entrepreneur and founder of Affirm; Dr. Michael Snyder, Chair of Genetics and Director of Personalized Medicine at Stanford University; and Dr. Garry Choy, a physician, radiologist, and former Chief Medical Information Officer at Massachusetts General Hospital. The idea emerged from the founders’ vision to create a “Star Trek MedBay” — a futuristic, comprehensive physical exam powered by AI and whole-body scanning technology. Early traction included backing from top venture capital firms such as Andreessen Horowitz, Khosla Ventures, Founders Fund, and SciFi VC, as well as a major investment from Kaiser Foundation Hospitals, validating the platform’s potential in personalized medicine[1][3][4].
Q Bio rides the growing trend of personalized medicine and digital health, leveraging advances in AI, genomics, and imaging to shift healthcare from reactive treatment to proactive prevention. The timing is critical as healthcare systems increasingly adopt digital tools to manage chronic diseases and improve patient outcomes cost-effectively. Market forces such as rising healthcare costs, demand for precision medicine, and technological maturation of AI and imaging create a favorable environment. By pioneering clinical digital twins, Q Bio influences the broader ecosystem by setting new standards for comprehensive health data integration and predictive analytics, potentially transforming how physical exams and preventive care are delivered[1][4].
Looking ahead, Q Bio is positioned to expand its clinical footprint and partnerships, scaling its platform to more healthcare providers and patient populations. Trends shaping its journey include advances in AI interpretability, integration with genomic and biomarker data, and growing consumer demand for personalized health insights. As digital twin technology matures, Q Bio’s influence may extend beyond preventive care into treatment simulation and precision therapeutics. Its success will depend on continued innovation, regulatory acceptance, and integration into mainstream healthcare workflows, potentially making the “physical exam of the future” a standard of care[1][4].
Q Bio has raised $84.0M in total across 3 funding rounds.
Q Bio's investors include 305 Ventures, Amadeus Capital Partners, FirstMark Capital, Khosla Ventures, NFX, Point72 Ventures, RX3 Growth Partners, Section 32, Valia Ventures, VZVC, What If Ventures, Andy Coravos.
Q Bio has raised $84.0M across 3 funding rounds. Most recently, it raised $27.0M Venture Round in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $27.0M Venture Round | 305 Ventures, Amadeus Capital Partners, FirstMark Capital, Khosla Ventures, NFX, Point72 Ventures, RX3 Growth Partners, Section 32, Valia Ventures, VZVC, What If Ventures, Andy Coravos, Kevin Hart, Yumin Choi | |
| Feb 1, 2020 | $40.0M Series B | Amadeus Capital Partners, Khosla Ventures, NFX, Point72 Ventures, RX3 Growth Partners, VZVC, Kevin Hart | |
| Dec 1, 2017 | $17.0M Series A | Amadeus Capital Partners, Khosla Ventures, Point72 Ventures |